Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.1
CABP is a leading cause of hospitalization and death in adults, especially the elderly.2 Causative bacterial pathogens include Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Chlamydophila pneumoniae, and Legionella species.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia. JAMA. 2019;322(17):1709–1710. doi:https://doi.org/10.1001/jama.2019.16482
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: